Literature DB >> 19880065

Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.

Donald Poon1, Benjamin O Anderson, Li-Tzong Chen, Koichi Tanaka, Wan Yee Lau, Eric Van Cutsem, Harjit Singh, Wan Cheng Chow, London Lucien Ooi, Pierce Chow, Maung Win Khin, Wen Hsin Koo.   

Abstract

Asia has a disproportionately large share of the world's hepatocellular carcinoma (HCC), mainly because of the endemic status of chronic hepatitis B and C viruses, which leads to liver cirrhosis and an increased risk of HCC. This etiological factor presents important opportunities for prevention, early detection, diagnosis, and treatment of HCC. This consensus statement reviews the available medical evidence for management of HCC in Asia, and gives treatment recommendations that are adapted to resource availability in this diverse region with disparate health-care delivery systems.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19880065     DOI: 10.1016/S1470-2045(09)70241-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  144 in total

1.  High expression level of EDIL3 in HCC predicts poor prognosis of HCC patients.

Authors:  Jian-Cong Sun; Xiao-Ting Liang; Ke Pan; Hui Wang; Jing-Jing Zhao; Jian-Jun Li; Hai-Qing Ma; Yi-Bing Chen; Jian-Chuan Xia
Journal:  World J Gastroenterol       Date:  2010-09-28       Impact factor: 5.742

2.  Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival.

Authors:  Manuel Hernández-Guerra; Alejandro Hernández-Camba; Juan Turnes; Luis Martin Ramos; Laura Arranz; José Mera; Javier Crespo; Enrique Quintero
Journal:  United European Gastroenterol J       Date:  2015-06       Impact factor: 4.623

3.  Early diagnosis of hepatocellular carcinoma by microRNAs: shining a light from the genome's "dark matter".

Authors:  Alejandro H Corvalan
Journal:  Dig Dis Sci       Date:  2012-11       Impact factor: 3.199

4.  Utilization of interventional oncology treatments in the United States.

Authors:  Sharon W Kwan; Robert K Kerlan; Jonathan H Sunshine
Journal:  J Vasc Interv Radiol       Date:  2010-05-15       Impact factor: 3.464

5.  AU-binding factor 1 expression was correlated with metadherin expression and progression of hepatocellular carcinoma.

Authors:  Yingzhuo Yang; Peng Kang; Jie Gao; Chunlin Xu; Shimei Wang; Haiyu Jin; Yunling Li; Wenjuan Liu; Xia Wu
Journal:  Tumour Biol       Date:  2013-11-09

6.  CCR6+ B lymphocytes responding to tumor cell-derived CCL20 support hepatocellular carcinoma progression via enhancing angiogenesis.

Authors:  Huan He; Jianxiong Wu; Mengya Zang; Weihu Wang; Xiuli Chang; Xiangmei Chen; Ruijun Wang; Zhiyuan Wu; Liming Wang; Dongmei Wang; Fengmin Lu; Zongtang Sun; Chunfeng Qu
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

7.  Targeting and eradicating hepatic cancer cells with a cancer-specific vector carrying the Buforin II gene.

Authors:  Yanyun Wang; Lili Qu; Lailing Gong; Li Sun; Rujun Gong; Jin Si
Journal:  Cancer Biother Radiopharm       Date:  2013-06-25       Impact factor: 3.099

8.  Hepatocellular carcinoma after ablation: the imaging follow-up scheme.

Authors:  Lin-Na Liu; Hui-Xiong Xu; Yi-Feng Zhang; Jun-Mei Xu
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

9.  A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis.

Authors:  Hashem B El-Serag; Fasiha Kanwal; Jessica A Davila; Jennifer Kramer; Peter Richardson
Journal:  Gastroenterology       Date:  2014-01-23       Impact factor: 22.682

Review 10.  Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma.

Authors:  Chihwan Choi; Gi Hong Choi; Tae Hyun Kim; Masatoshi Tanaka; Mao-Bin Meng; Jinsil Seong
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.